Statins do not prevent acute organ failure in ventilated ICU patients: single-centre retrospective cohort study

Marius J. Terblanche*, Ruxandra Pinto, Craig Whiteley, Stephen Brett, Richard Beale, Neill K. J. Adhikari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Introduction: Observational studies suggest statin therapy reduces incident sepsis, but few studies have examined the impact on new organ failure. We tested the hypothesis that statin therapy, administered for standard clinical indications to ventilated intensive care unit patients, prevents acute organ failure without harming the liver.

Methods: We performed a retrospective, single-centre cohort study in a tertiary mixed medical/surgical intensive care unit. Mechanically ventilated patients without nonrespiratory organ failure within 24 hours after admission were assessed (during the first 15 days) for new acute organ failure (defined as Sequential Organ Failure Assessment (SOFA) score 3 or 4), liver failure (defined as new hepatic SOFA >= 3, or a 1.5 times increase of bilirubin from baseline to a value >= 20 mmol/l), and alanine transferase (ALT) > 165 IU/l. The effect of statin administration was explored in generalised linear mixed models.

Results: A total of 1,397 patients were included. Two hundred and nineteen patients received a median (interquartile range) of three (two, eight) statin doses. Patients receiving statins were older (67.4 vs. 55.5 years, P <0.0001), less likely female (25.1% vs. 37.9%, P = 0.0003) and sicker (Acute Physiology and Chronic Health Evaluation (APACHE) II score 20.3 vs. 17.8, P <0.0001). Considering outcome events at least 1 day after statin administration, statin patients were equally likely to develop acute organ failure (28.4% vs. 22.3%, P = 0.29) and hepatic failure (9.5% vs. 7.6%, P = 0.34), but were more likely to experience an ALT increase to > 165 IU/l ((11.2% vs. 4.8%, P = 0.0005). Multivariable analysis showed that APACHE II score (odds ratio (OR) = 1.05 per point; 95% confidence interval (CI) = 1.03 to 1.07) and APACHE II admission category (P <0.0001), but not statin administration (OR = 1.21; 95% CI = 0.92 to 1.62), were significantly associated with acute organ failure occurring on or after the day of first statin administration. Statin administration was not associated with liver impairment (OR = 1.08; 95% CI = 0.66 to 1.77) but was associated with a rise in ALT > 165 IU/l (OR = 2.25; 95% CI = 1.32 to 3.84), along with APACHE II score (P = 0.016) and admission ALT (P = 0.0001).

Conclusions: Concurrent statin therapy does not appear to protect against the development of new acute organ failure in critically ill, ventilated patients. The lack of effect may be due to residual confounding, a relatively low number of doses received, or an absence of true effect. Randomised controlled trials are needed to confirm a protective effect.

Original languageEnglish
Article numberR74
Number of pages10
JournalCRITICAL CARE
Volume15
Issue number1
DOIs
Publication statusPublished - 28 Feb 2011

Keywords

  • SYSTEMIC INFLAMMATORY RESPONSE
  • ILL INFECTED PATIENTS
  • ACUTE LUNG INJURY
  • CLINICAL-TRIAL
  • SEVERE SEPSIS
  • THERAPY
  • PROGRESSION
  • SEVERITY
  • BIAS

Fingerprint

Dive into the research topics of 'Statins do not prevent acute organ failure in ventilated ICU patients: single-centre retrospective cohort study'. Together they form a unique fingerprint.

Cite this